The results of long-term permixon® treatment in patients with symptoms of lower urinary tractsdysfunction due to benign prostatic hyperplasia


Cite item

Full Text

Abstract

The trial enrolled 155 patients (mean age 65 years) with documented
benign prostatic hyperplasia and lower urinary tracts symptoms
(LUTS) (IPSS > 6). All the patients received permixon m a dose
160 mg twice a day for 2 years. The data on 130 patients eligible for
assessment were processed statistically by dynamics of IPSS, quality
of life (QOL), index of sexual function (MSF-4), size of the prostate
urodynamic and biological parameteers which were estimated in 6
(V6) 12 (V12), 18 (V18) and 24 months (V24). Clinical examination
with registration of all side effects was made each 3 months. Permixon
was found to noticeably reduce IPSS and QOL and increae maximal
urine flow speed. The size of the prostate diminished insignificantly.
Sexual function remained unchanged for 1 year and improved markedly
within the second year (p = 0.001). Permixon had no effect on
the level of prostate-specific antigen. Plasma hormones (testosterone,
DHT, estradiol, LH, androstendion) did not change. Nine patients
developed 10 side effects but they were unrelated to the treatment

References

  1. Berry S. J., Coffey D. S., Walsh P. C., Ewing L. The development of human benign prostatic hypertrophy with age. J. Urol. (Baltimore). 1984; 132: 474-479.
  2. Holtgrewe H. L. Current trends in management of men with lower urinary tract symptoms and benign prostatic hyperplasia. Urology 1998; 51 (suppl. 4): 1-7.
  3. Chacon A., Monga M. Medical management of benign prostatic hyperplasia. Geriatr. Nephrol. Urol. 1999; 9 (1): 39-48.
  4. Clifford G. M., Farmer R. D. Medical therapy for benign prostatic hyperplasia: a review of the literature. Eur. Urol. 2000; 38 (1):2-19.
  5. Djavan В., Marberger M. A meta-analysis on the efficacy and tolerability of aladrenoceptors antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur. Urol. 1999; 36 (1): 1-13.
  6. Carraro J. C., Raynaud J. P., Koch G. etal. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostatic hyperplasia: a randomised international study of 1,098 patients. Prostate 1996; 29 (4): 231-240.
  7. Lepor H., Williford W. O., Barry M. J. et al. The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N. Engl. J. Med. 1996; 33 (8): 533-539.
  8. Buck A. C. Phytotherapy for the prostate. Br. J. Urol. 1996; 78: 325-336.
  9. Wilt T. J., Fshani A., Stark G. et al. Saw Palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. J. A. M. A. 1998; 280 (18): 1604-1609.
  10. Lowe F. C., Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia: an update. Urology 1999; 9 (1): 39- 48.
  11. Paubert-Braquet M., Cousse H., Raynaud J. P. et al. Effect of the lipidosterolic extract of Serenoa repens and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur. Urol. 1998; 33: 340-347.
  12. Iehle C., Delos S., Guirou O. et al. Human prostatic steroid 5 alpha-reductase isoforms. A comparative study of selective inhibitors. J. Steroid Biochem. Mol. Biol. 1995; 54: 273-279.
  13. Bayne С. W., Donnelly F., Ross M., Habib F. K. Serenoa repens (Permixon): a 5 alpha-reductase types I and II inhibitor - new evidence in a coculture model of BPH. Prostate 1999; 40 (4): 232-241.
  14. Boyle P., Robertson C., Lowe F., Roehrborn С. Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 2000; 55 (4): 533-539.
  15. Debruyne F., Koch G., Boyle P. et al. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomised international study. Eur. Urol. 2002; 41 (3): 497- 507.
  16. Marquis P., Marrel A. Reproducibility and clinical concurrent validity of the MSF-4: a four item male sexual function questionnaire for patients with benign prostatic hyperplasia. Value in HItli 2001; 4 (4): 335-343.
  17. Eri L. M., Tveter К. J. Alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia. J. Urol. (Baltimore) 1995; 154(3): 923-934.
  18. Abrams P., Schulman C., Vaage S. Tamsulosin, a selective alphalc adrenoreceptor antagonist: a randomised, controlled trial in patients with benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group. Br. J. Urol. 1995; 76 (3): 325-326.
  19. Chappie C., Wyndaele J., Nordling J. et al. Tamsulosin, the first prostate-selective alpha-la adrenoceptor antagonist. A metaanalysis of two randomised, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur. Urol. 1996; 29 (2): 155-167.
  20. Denis L., Griffiths S., Khoury S. et al. In: Proceedings of the 4- th Internationa] consultation on benign prostatic hyperplasia (BPH). Paris; 1997. 439-491.
  21. Plosker G. L., Brogden R. N. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 1996; 9 (5): 379-395.
  22. Marberger M. on behalf of the PROWESS study group. Longterm effect of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicentre study. Urology 1998; 51: 677-686.
  23. Stepanov V. N., Siniakov L. A., Sarrazin В., Raynaud J. P. Efficacy and tolerability of the lipido-sterolic extract of Serenoa repens (Permixon) in benign prostatic hyperplasia: a doubleblind comparison of two dosage regimens. Adv. Ther. 1999; 16 (5): 231-241.
  24. Schulman C., Cortvriend J., Jonas U. et al. Tamsulosin: 3 year long term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European multinational, multicenter, open-label study. Eur. Urol. 1999; 36: 609-620.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2004 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies